The Rovati family, less than a month after the about-face on the stock market listing, sells the pharmaceutical group Rottapharm Madaus to the Swedish Meda Ab, listed in Stockholm with a capitalization of 3,5 billion euros. The agreement between Meda – assisted by Rothschild – and the Rovati holding company, Fidim, values Rottapharm at 2,275 billion euros, well above the values circulated during the IPO.
The consideration - reads a note - provides for a cash component of 1 billion and 643 million (to which a further 275 million will be added which will be paid in January 2017), and a share component, through a capital increase reserved for Fidim, equal to 357 million. Upon completion of the transaction, Fidim will hold a 9% stake in the capital of Meda AB, becoming its second largest shareholder. All R&D activities dedicated to the high-tech drug segment headed by Rottapharm Biotech, the historic core of the group's research, are excluded from the agreement.
